Boston Scientific (NYSE:BSX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Boston Scientific to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Volatility & Risk
Boston Scientific has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Boston Scientific’s rivals have a beta of 2.58, indicating that their average stock price is 158% more volatile than the S&P 500.
Insider & Institutional Ownership
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Boston Scientific and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Boston Scientific | 2 | 8 | 20 | 1 | 2.65 |
| Boston Scientific Competitors | 4310 | 10598 | 18377 | 838 | 2.46 |
Boston Scientific presently has a consensus target price of $61.43, suggesting a potential upside of 38.59%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.24%. Given Boston Scientific’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Boston Scientific is more favorable than its rivals.
Profitability
This table compares Boston Scientific and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Boston Scientific | 16.62% | 18.61% | 10.58% |
| Boston Scientific Competitors | -270.28% | -155.47% | -22.38% |
Valuation & Earnings
This table compares Boston Scientific and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Boston Scientific | $20.07 billion | $2.90 billion | 18.78 |
| Boston Scientific Competitors | $1.91 billion | $136.81 million | 5.72 |
Boston Scientific has higher revenue and earnings than its rivals. Boston Scientific is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Boston Scientific beats its rivals on 11 of the 13 factors compared.
Boston Scientific Company Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
